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ABSTRACT
Cardiovascular disease (CVD) has taken up to average 30% of death diagnoses in the 
world. Prevalent attempts of physicians to treat this disease came down to focus on using 
drugs with their specific mechanism of action. Since the method only cures the symptoms 
and need to be pharmacologically monitored, physicians and scientists have been strug-
gling to find other treatment strategies. This problem led us to search for another substance 
dealing with CVD via preventive therapy, which does not require such close monitoring 
by physicians in its use. The answer relies on using L-citrulline as potential therapeutics 
in treating and preventing CVDs. This compound, found mostly in Citrus sp., contains 
chemical traits that could affect other bodily substances with its metabolic pathways. It 
has several functions, but boosting NO production is the dominant one in the cardiovascu-
lar system. By enhancing NO bioavailability, it suppresses the risk of having myocardial 
oxidative stress due to ischemia, cardiac pressure-overload, and post-infarct reperfusion. 
Thus, understanding of L-citrulline effects on endothelial NOS pathway in the generation 
of NO and its uncoupling mechanisms could be used as a foundation in developing alter-
native treatment and prevention of oxidative stress-induced CVD. 
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INTRODUCTION
Cardiovascular disease (CVD) has been the most common 
nationwide cause of death. It accounts for average 
30% ultimate cause of death in both developed and 
developing countries. The era of rapid industrialization 
and urbanization has promoted higher emergent of the 
diseases, with some examples such as pathological 
cardiac hypertrophy, myocardial infarction, and cardiac 
valve lesions. Risk factors increasing probability of 
suffering CVDs include the molecular scope of genetics 
into wide exposure of environmental factors (Loscalzo 
& Harrison, 2013).
Physicians’ attempts to relieve CVDs have come down 
into usage of specific pharmacological strategies, such as 
antihypertensive agents or diuretics. Although they are 
often deployed to treat CVDs with such low therapeutic 
index, their amounts in blood plasma must be controlled 
very carefully to minimize any adverse effects (Katzung 
et al., 2015). Since the method only cured symptoms 
and needed to be pharmacologically monitored, 
physicians and scientists have been struggling to find 
other treatment strategies. This problem led us to search 
for another substance dealing with CVD via preventive 
therapy, which does not require such a close monitoring 
by physicians in its use. The proximate and ultimate 
answer for these problems is yes. It is L-citrulline. 
L-citrulline is known to have potential therapeutics in 
relieving CVDs. Following discussions of L-citrulline 
are explained further into its molecular structure, 
biochemistry, pharmacology, physiology, as well as its 
utilization in treating cardiovascular system. 
L-citrulline is a non-essential amino acid classified 
specifically as a non-protein monomer (Kaore & Kaore, 
2014). It means that L-citrulline cannot be used as raw 
material in cellular protein synthesis, except that it 
emerges as post-translational modification or Golgi’s 
products. L-citrulline does not charge with tRNA 
normally as it does not correspond within the known 
20 types of amino acids. Moreover, it is discovered 
in muskmelons, squashes, gourds, cucumbers, and 
pumpkins, as well as watermelons. Watermelons or 
Citrus vulgaris are the ones contain lots of L-citrulline, 
which constitutes approximately 2.1 mg per gram of fresh 
weight (Frank et al., 2017). Schematic representation of 
watermelon functions can be seen in Figure 1. 
L-citrulline may serve as antioxidant that prevents DNA 
damage-induced oxidative stress and reticuloendothelial 
system over activity. L-citrulline could also enhance 
muscle protein synthesis, reduce gastrointestinal 
tract injury during exercise, and improve blood-
tissue perfusion. In this review, focus of L-citrulline 
activities would be in the cardiovascular system.  Any 
supplementation of L-citrulline for human could be 
obtained through chemical industries, genetically 
modified microorganisms, or enzymatic reaction (Jiang 
et al., 2017).
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Figure 1.    Watermelon (Citrus vulgaris) contains citrulline that promotes vasodilation, 
antioxidation, anti-inflammation, and healthy hepato-hematological functions Hong M et al., 2015.
COX-2: cyclooxygenase 2, CRP: c-reactive protein, CVD: cardiovascular disease, HDL: high density 
lipoprotein, LDL: low density lipoprotein, NO: nitric oxide, NOS: nitric oxide synthase, RelA: NF-
kappa-B p65 subunit, TC: total cholesterol, TG: triglyceride
Biochemistry of L-citrulline
Chemical Characteristics of L-citrulline
L-citrulline is a non-protein amino acid with C6H13N3O3 
alpha-structured configuration withmolecular mass 
175.19 Dalton. Its high solubility in water makes it 
perfect for oral administration via aqueous solution. 
Available in white powder form and alkalized-smell, 
its natural structure is often discovered in levorotatory 
stereoisomerization. Considering its hydrophilic custom, 
high intake of L-citrulline orally might cause osmotic 
diarrhea (Kaore & Kaore, 2014).  Molecular structure of 
L-citrulline can be seen in Figure 2.
Metabolism and Biosynthesis of L-citrulline
L-citrulline is biosynthesized through nitric oxide and 
urea cycles.  Urea cycle covers up to 90% production of 
L-citrulline in hepatocytes (Frank et al., 2017). Arginine 
is first transformed into ornithine by arginase, releasing 
urea into blood plasma to be further cleared via kidneys 
(Kaore & Kaore, 2014). Ornithine then combined with 
carbamoyl phosphate as constituents of ammonia to 
form citrulline by the enzymatic activity of ornithine 
carbamoyltransferase (Frank et al., 2017). Besides, 
citrulline could be metabolized back into arginine using 
argininosuccinate as intermediates by argininosuccinate 
synthase and lyase (Mori et al., 2015).
Another process involved in the generation of 
L-citrulline is the nitric oxide cycle in blood vessels 
Figure 2. Molecular structure of L-citrulline 
(Kaore S et al., 2014)
which covers up 10% production of plasma L-citrulline 
(Frank et al., 2017). Direct transformation of arginine 
into citrulline using nitric oxide synthase gives out NO 
into plasma. Reverse metabolism from citrulline into 
arginine is associated with the same pathway using 
argininosuccinate as biosynthetic intermediate (Jiang et 
al., 2017). In double-blind randomized research cross-
over design, supplementation of L-citrulline could 
remove any excess ammonia accumulation in blood, 
alleviating any central fatigue in athletes (Chen et al., 
2016). Detail schematic metabolism of L-citrulline can 
be seen in Figure 3 and 4. 
Although nitric oxide cycle only constitutes tiny part 
of L-citrulline production, it gives the biggest point 
of information regarding mechanisms of L-citrulline 
towards cardiovascular system. Studies conducted to 
prove this hypothesis explained that consumption of 
Citrus vulgaris regularly would resist cellular damage 
due to its antioxidative activity. As Citrus sp. elevates 
plasma concentration of L-citrulline, it encourages the 
bioavailability of NO gas throughout systemic and 
pulmonary blood vessels. This condition provide basis 
for applying L-citrulline in promoting cardiovascular 
health (Hong et al., 2015).
Physiological Mechanisms of L-citrulline in 
Cardiovascular System
L-citrulline: Nitric Oxide Production Booster
NO is a rapidly diffusing gaseous molecule that is 
released at several locations, such as vascular endothelial 
cells, neurons, and glial cells. It acts as vasodilator by 
relaxing vessels’ smooth muscle. Production of NO gas 
is done by nitric oxide synthase using L-arginine as 
primary substrate in the NO cycle. L-citrulline, in this 
NO cycle, could be in paradoxical functions: precursor of 
L-arginine or byproducts of L-arginine metabolism while 
making NO as well (Lorin et al., 2014). Supplementation 
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of L-citrulline orally increases plasma concentration of 
L-arginine. Additionally, arginine is then metabolized 
back into citrulline via either urea or nitric oxide cycle 
(Kurauchi et al., 2017). Beside the use of L-citrulline 
as single agent, the combination of L-arginine and 
L-citrulline supplementation would further increase 
the amount of plasma citrulline (Suzuki et al., 2017). 
Metabolic balance manages the whole concentration of 
arginine and citrulline itself in blood plasma. Graphical 
presentation between L-citrulline administration and 
amount of plasma citrulline is explained in Figure 5. 
In vascular endothelium, NO is released by endothelial 
nitric oxide synthase (eNOS)  involving L-arginine and 
L-citrulline as substrate and product respectively (Incalza 
et al., 2017). Adequate L-citrulline supplementation 
gradually activates NO production due to recycling of 
L-citrulline into L-arginine. As a result, L-citrulline 
Figure 3. L-citrulline in metabolic pathways: urea and nitric oxide cycle (Frank et al., 2017).
Figure 4. L-citrulline metabolism in liver, enterocytes, and kidneys. 
Note that L-citrulline could be used as biomarker (Kaore et al., 2014).
would indirectly increase NO levels in plasma (Mori 
et al., 2015). Furthermore, NO does not exist long 
enough in plasma soon after its release. Its maximum 
distance of diffusion is 300 µm with half-life of 0.05-1.8 
milliseconds (Mori et al., 2015). Relationship between 
L-citrulline and plasma NO is explained in Figure 6. 
Effects of L-citrulline on Plasma Amino Acids and 
other Substances 
Not only L-citrulline increase nitric oxide levels in blood, 
but also it reduces plasma GSH which then dramatically 
decrease the degradation of NO by oxidation. As a 
matter of fact, serum nitrite (NO2-) concentration elevate 
significantly (Frank et al., 2017).  NO2- ion would be 
reduced to become NO under ischemic condition  (Kaore 
& Kaore, 2014). Furthermore, L-citrulline affects certain 
substances in plasma; for example, glutamine, ornithine, 
and arginine. Arginine is transformed into L-citrulline 
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Figure 5. Plasma concentration-time profile of 
citrulline followed by continuous intravenous 
infusion after citrulline bolus administration. For 
comparison, citrulline plasma levels under similar 
procedures without citrulline treatments 
(Barr F et al., 2007).
Figure 6. Plasma concentration-time profile of 
nitric oxide followed by continuous intravenous 
infusion after citrulline bolus administration. For 
comparison, citrulline plasma levels under similar 
procedures without citrulline treatments. 
(Barr F et al., 2007).
to generate ATP by enzymatic reaction of arginine 
deiminase, ornithine transcarbamoylase, and carbamate 
kinase. Because of sufficient L-citrulline is found in 
blood plasma, the backward mechanisms occur, which 
is the transformation of L-citrulline into arginine via 
argininosuccinate synthase (ASS) and argininosuccinate 
lyase (ASL) (Jiang et al., 2017).
Other amino acids are not significantly affected. 
L-citrulline provides serum buffering effect through 
the retention of plasma bicarbonate, for it is absorbed 
as equally as the urea is excreted (Frank et al., 2017).  
Since the urea is formed through urea cycle involving 
L-citrulline, it is therefore needed to be cleared along 
urine. 
Other Functions of L-citrulline
L-citrulline is one of the potent hydroxyl radical scavengers 
that prevents excessive release of superoxide anion (O2-) 
as oxidative stress may happen in any ischemic tissues. 
L-citrulline could also become biomarker for certain 
inflammation, such as that citrullinated joint protein 
prone to autoantibodies attack in rheumatoid arthritis. 
(Kaore & Kaore, 2014) L-citrulline is also considered to 
be a powerful anabolic amino acid because it increases 
the rate of muscle protein synthesis. Therefore, weight 
gain is observed with massive reconstruction in muscular 
system (Jiang et al., 2017).
Pharmacological Mechanisms of L-citrulline 
Pharmacodynamics of L-citrulline
No direct pharmacological effect of L-citrulline towards 
cells has been observed, but it is known to associate 
closely with the pharmacodynamics of NO gas. (Kaore 
& Kaore, 2014) Thus, L-citrulline balances systemic 
and pulmonary vascular tone by promoting vasodilation. 
This is done under the function of NO in activating 
membrane signaling enzyme, that is guanylyl cyclase. 
Dephosphorylation and cyclization of GTP into cGMP 
intensifies the amplification of Cyclooxygenase-1/cGMP 
signaling cascades that cause vessels’ smooth muscles to 
relax (Mori et al., 2015).
L-citrulline is observed to relieve pulmonary arterial 
hypertension since it manifests in its ability to vasodilate. 
However, it induces neither systemic hypotension nor 
tachycardia. Besides, that no dramatic reduction of 
Figure 7. Mean blood pressure did not differ 
between oral and placebo groups. P = 0.53. Mean 
and standard deviation are shown for each group 
for 48-hour period (Xuan C et al., 2015).
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Table 1. Risk of pulmonary hypertension with plasma citrulline. Its relative risk of suffering 
pulmonary hypertension is significantly lower with more than 37 µM plasma citrulline 
treatment.14
Plasma Citrulline 12 h 
Postoperatively
Pulmonary 
Hypertension 
Absent
Pulmonary 
Hypertension 
Present
P value
< 37 µmol/L 18 9 .036
37 µmol/L 12 *0
mean arterial pressure is seen after administration of 
L-citrulline is needed to be studied further (Heidi et 
al., 2007). Association between citrulline and MAP can 
be seen in Figure 7. Additionally, protective effect of 
L-citrulline in relieving pulmonary hypertension risk is 
explained in Table 1. 
Pharmacokinetics of L-citrulline
L-citrulline is well absorbed in enteral route. Its 
bioavailability in this route would be reduced to 
certain concentration, since it faces first-pass effect in 
the liver. Despite its conversion to other substances, 
constant supplementation of oral L-citrulline marked a 
linear and dose-dependent increase of plasma citrulline 
(Schwedhelm et al., 2008). The optimal dosage of 
L-citrulline is controlled by liver and kidneys. As a result, 
latter restriction of plasma citrulline elevation occurs 
after excessive supplementation of oral L-citrulline. In 
addition, 83% of ingested citrulline will be taken up 
by kidneys to be transformed into L-arginine (Kaore & 
Kaore, 2014).
Enteral absorption of L-citrulline requires sodium-
dependent cotransporter. Comparing to arginine, 
L-citrulline enters bloodstream much easier from 
intestinal lumen. It also provides buffering effect to other 
metabolic substances, especially arginine, involving urea 
cycle, NO cycle, and arginine biosynthesis. That is why 
it is safer and efficient to replenish plasma arginine using 
L-citrulline than directly using arginine (Kurauchi et al., 
2017).
Effective dosage of L-citrulline in human is estimated 
to be 40 mg/kg body weight with maximum 15 g of 
L-citrulline per oral administration (Frank et al., 2017). 
Clearance of plasma citrulline in kidneys is estimated 
to be 0.6 L/kg/h with volume of distribution 0.9 L/
kg for 60-minute plasma half-time (Barr et al., 2007). 
Maintenance of certain plasma citrulline levels needs 
calculation involving citrulline infusion intravenously 
(Barr et al., 2007) . Graphical presentations of L-citrulline 
pharmacokinetics in one study can be seen in Figure 8. 
Protection of L-citrulline Against Cardiovascular 
Disease
Some CVDs has been recognized along to be related 
with oxidative stress; for example, hypertrophic 
cardiomyopathy, cardiac remodeling, and myocardial 
infarction. They manifest in the apoptosis or necrosis 
of normal cardiac myocytes. Some of these disorders 
are even maintained in certain body conditions or drug-
induced states. Furthermore, molecular pathophysiology 
Figure 8. Pharmacokinetic modeling of IV administered bolus of citrulline, followed by 
4 hours later by infusion. Bolus dose of 150 mg/kg was determined most likely to yield 
4-hour trough of 80-100 µM, and infusion of 9 mg/kg/h was predicted to achieve steady 
state. Note that the plasma half time is 60 minutes with dose-dependent increase along 
with the added bolus dosage (Barr F et al., 2007).
Laurentius, et al.
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Figure 9. a) Generation of NO and L-citrulline via electron transfer in NOS 
pathway. Note that the electron is taken up from NADPH domain in order to 
reduce heme domain for both L-citrulline and NO synthesis. b) Uncoupling 
mechanisms compensating for low BH4 cofactor and substrate L-arginine. 
Note that superoxide anion replaces nitric oxide as byproducts of this pathway 
(Incalza M et al., 2017).
involving the generation of reactive oxygen species 
(ROS) and reactive nitrogen species (RNS) of these 
diseases is the ultimate ‘culprit’. Hence, comprehension 
in the ROS/RNS generation mechanisms would give 
beneficial effect of using L-citrulline to counteract their 
pathological activities.
Pathophysiology of Oxidative Stress-induced 
Cardiovascular Diseases
Reactive oxygen species are hyperreactive intermediates 
of oxygen-related molecules, which are generated 
physiologically in mitochondria as byproducts of 
oxidative phosphorylation. RNS have similar chemical 
characteristics with ROS but with different element 
participated, that is nitrogen. Several examples of ROS/
RNS are hydrogen peroxide (H2O2), superoxide anion 
(O2-), oxygen nascent (O.), and peroxynitrite (ONOO-). 
They are generated as a result of incomplete amounts 
of electrons in their atomic valence shell. Destructive 
activities of these species, to fulfill their outer electron shell, 
are highly related to their oxidative reaction. Oxidation 
of nuclear materials, membrane fragmentation, cellular 
autolysis, and protein digestion are the devastating ones. 
Oxidative stress happens when ROS/RNS levels exceeds 
the capability of antioxidant defense system to suppress 
them. Cellular ischemia or hypoxia would be the most 
dominant factor in triggering oxidative stress. In this 
case, myocardial ischemia may happen to cause oxidative 
stress. Post-infarct angiogenesis and fibrosis may lead to 
ischemic-reperfusion injuries that cause more oxidative 
damages within nearby cells. In this way, myocardial 
infarction develops other complications as main effects 
of cellular oxidative stress (Incalza et al., 2017). Besides 
myocardial infarction, cardiac remodeling also induces 
oxidative attacks. Excessive cardiac hypertrophy due 
to remodeling increased contractility, but with much 
lower end-diastolic blood volume. This means that it is 
designed to compensate reduced cardiac output due to 
aortic stenosis, high cardiac afterload, et cetera. Lower 
amount of blood stroked with powerful ventricular 
contraction would dramatically decrease the perfusion 
of blood into myocardium via coronary arteries. Greater 
and greater impact of oxidative stress could gradually 
deteriorate cardiac physiology into vicious cycle of heart 
failure. 
In the situation where cells are experiencing 
oxidative stress, formation of peroxynitrite occurs 
most. Peroxynitrite is a radical molecule resulted 
from the combination of NO and O2- via a pathway 
called eNOS uncoupling (Moens et al., 2011). The 
‘uncoupling’ mechanism involves  decreased amount of 
tetrahydrobiopterin (BH4) which normally stabilize the 
dimerization of NOS enzyme (Moens et al., 2011). This 
structure optimally facilitates the transfer of electron 
from NADPH in its reductase domain to heme group 
in its oxidase domain to convert arginine into citrulline 
by generating NO gas (Tang et al., 2014). Relative 
subtraction of BH4 cofactor in NOS is primarily caused 
by oxidation of BH4 into dihydrobiopterin (BH2) via 
oxidative stress (Moens et al., 2011). As a result, partial 
transfer of electrons in non-dimer NOS might lead to 
generation of superoxide anion, instead of nitric oxide 
(Tang et al., 2014). Further destruction of cells due to 
78 Pharm Sci Res, Vol 5 No 2, 2018
ISSN 2407-2354
peroxynitrite slowly damage heart pump ability to fulfill 
metabolic demands (Tang et al., 2014) eNOS uncoupled 
mechanisms can be seen in Figure 9. 
Protective Effects of L-citrulline Towards Oxidative 
Stress
Because L-citrulline is seen to maintain vascular NO 
level, L-citrulline potentially reverses the damaging 
effects of oxidative stress in cardiovascular system. 
L-citrulline is known to upregulate the expression rate of 
normal eNOS enzyme, subsequently compensating for 
the uncoupled activity eNOS (Xuan et al., 2015) . NO is 
the key modulator of cardiac function through regulation 
of myocytes contraction and growth (Tang et al., 2014). 
NO activates cGMP signaling cascades that eventually 
modifies NOS protein post-translationally by adding 
nitrosyl group in free thiol of its cysteine residue (Tang et 
al., 2014). Thiol-nitrosylation of cysteine residue firmly 
hold the dimer structure of NOS, subsequently reducing 
O2- production (Tang et al., 2014). In this condition, 
NO could prevent formation of atherosclerotic plaques, 
excessive ventricular hypertrophy, as well as pulmonary 
arterial hypertension (Van Deel et al., 2015). It also 
counteracts complication of hypercholesterolemia and 
diabetes mellitus (Moens et al., 2011). Disturbances 
in nitroso-redox balance, that tightly controls NO 
and O2- level, would finally cause oxidative stress. 
eNOS expression levels has been known to linked 
with aggravation of left ventricular hypertrophy and 
dysfunction in aortic stenosis-induced pressure overload. 
Knockout of eNOS gene would increase capillary density, 
fibrosis, and natriuretic peptide expression in heart, 
rising the risk of cardiac oxidative stress (Van Deel et al., 
2015). L-citrulline is known to reduce systemic arterial 
stiffness at rest and aortic pressure responses to cold-
pressor test. Randomized controlled study of L-citrulline 
supplementation could attenuate any exaggerated arterial 
stiffness regarding either combined metaboreflex or cold 
exposure; thus, this piece of evidence might provide 
insight on potential protection against increased cardiac 
afterload during physical stress (Figueroa et al., 2016).
Chronic and long-term administration of NO as 
prophylaxis would affect vascular tone, or further induce 
formation of radical molecules (Xuan et al., 2015). That 
is why it would be best to increase NO bioavailability 
and balancing nitroso-redox system via NO cycle, using 
L-citrulline as substrate. Thus, L-citrulline serves to 
protect against cardiovascular disease in the sense of 
preventing cellular oxidative stress.
Clinical trials: L-citrulline Towards Cardiovascular 
Diseases
Advanced application of L-citrulline has come to major 
clinical trials in hospitals. Improvement of six-minute 
walking test and quality of life of patients has been seen in 
patients with arterial pulmonary hypertension comorbid 
with Eisenmenger syndrome (Sharif et al., 2014) . 
Additionally, pre-exercise L-citrulline administration 
could enhance splanchnic perfusion, attenuating 
intestinal ischemia during strenuous exercise. It prevents 
occurrence of oxidative stress in the enterocytes due to 
increased number of adequately perfused small vessels 
compared to placebo (7.8 ± 6.0 vs. -2.0 ± 2.4, p = 0.06) 
(Van Wijck et al., 2014). Further studies include that 
assessment of L-citrulline in randomized cross over 
clinical trials of thirty patients diagnosed with coronary 
artery disease have shown significant improvement 
in endothelial function. Ratio flow mediated dilation 
(FMD) to nitroglycerin dependent vasodilation (NMD) 
in assessing endothelial function increases significantly 
conformed with statistical analysis (p < 0.001) after 
L-citrulline administration (Safi et al., 2017). Ultimately, 
utilization of L-citrulline in experimental clinical group 
consisting of 35 patients with systolic heart failure has 
successfully improved left ventricular ejection fraction 
(LVEF) up to 35% via evaluation though radioisotopic, 
ventriculography, and photoplethysmography (Balderas 
et al., 2012).
CONCLUSION 
Physicians and scientists’ approaches in managing 
CVDs regarding strategies’ simplicity, curability, and 
preventability had led to using L-citrulline as alternative 
pharmacological substance. Chemical characteristics 
of L-citrulline are closely related with its biosynthesis 
and metabolic processes. It provides wide range of 
plasma active dosage with minimal side-effect and is 
best administered orally or intravenously to reach its 
maximum bioavailability. Furthermore, its antioxidant 
capacity would be effective to prevent oxidative stress-
induced cardiovascular diseases. eNOS uncoupling, 
which produces more radical molecule, could be 
reversed by L-citrulline existence. Generating NO gas 
through transformation of L-citrulline into arginine in 
NO cycle would stabilizes the dimer structure of NOS; 
on the other hand, monomer NOS would produce O2
- 
as byproducts, instead of NO. Indirectly promoting 
vasodilation, reducing pulmonary hypertension, and 
regulating of ventricular ejection fraction are all functions 
of L-citrulline. Lastly, diverse advantages of L-citrulline 
in cardiovascular system is further comprehended to 
encourage its utilization in protecting against CVDs.
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